TEVA:NYE-Teva Pharma Industries Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 22.01

Change

+0.19 (+0.87)%

Market Cap

N/A

Volume

0.01B

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.90 (-0.54%)

USD 76.41B
HLN Haleon plc

-0.02 (-0.22%)

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A..

-0.21 (-1.60%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd..

+0.29 (+1.96%)

USD 12.60B
ELAN Elanco Animal Health

+0.06 (+0.50%)

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.47%)

USD 3.68B
BHC Bausch Health Companies Inc

+0.25 (+3.35%)

USD 2.91B
CPHI China Pharma Holdings Inc

-0.01 (-2.82%)

USD 3.69M
YCBD cbdMD Inc

-0.02 (-4.26%)

USD 1.96M
EBS Emergent Biosolutions Inc

+0.65 (+6.36%)

N/A

ETFs Containing TEVA

ISRA VanEck Israel ETF 10.44 % 0.60 %

-0.02 (0.15%)

USD 0.09B
FLWR:SW 5.80 % 0.00 %

N/A

N/A
THNR Amplify ETF Trust 4.81 % 0.00 %

+0.03 (+0.15%)

USD 4.08M
IDVO Amplify International Enh.. 3.56 % 0.00 %

-0.04 (0.15%)

USD 0.15B
GVIP Goldman Sachs Hedge Indus.. 2.49 % 0.45 %

+1.61 (+0.15%)

USD 0.32B
IS3T:XETRA iShares MSCI World Size F.. 0.17 % 0.00 %

-0.06 (0.15%)

USD 0.24B
IWFS:LSE iShares MSCI World Size F.. 0.17 % 0.00 %

+4.50 (+0.15%)

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.17 % 0.00 %

-0.02 (0.15%)

USD 0.28B
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

-0.19 (0.15%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
BOUT Innovator ETFs Trust - In.. 0.00 % 0.80 %

-0.23 (0.15%)

USD 0.01B
ISRPF iShares Public Limited Co.. 0.00 % 0.00 %

-0.09 (0.15%)

USD 2.22B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.12 (0.15%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

-0.10 (0.15%)

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

+0.01 (+0.15%)

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.14% 57% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.14% 57% F 22% F
Trailing 12 Months  
Capital Gain 83.88% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.88% 93% A 96% N/A
Trailing 5 Years  
Capital Gain 117.92% 100% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 117.92% 100% F 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 12.30% 71% C- 69% C-
Dividend Return 12.30% 64% D 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.59% 50% F 23% F
Risk Adjusted Return 28.89% 57% F 43% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector